Premier Alternatives

Therini Bio

Sacramento, CA · Founded 2016 · Privately Held (backing)

Developer of biotechnology drugs designed to offer a potential treatment to protect the nervous system from multiple sclerosis damage. Therini Bio is based in Sacramento, CA and was founded in 2016. It was valued at $100 million at its later-stage round in May 2025, the last priced event on record. It has raised $102 million across 2 recorded rounds; the latest was a $74.9 million later-stage round in Mar 2023.

PMV mark · valuation
$100.0M
Oct 2026
Priced at
its later-stage round
May 2025
Total raised
$101.5M
Last round
Later Stage VC
Mar 2023

Therini Bio key facts

as of Oct 2026
  • Developer of biotechnology drugs designed to offer a potential treatment to protect the nervous system from multiple sclerosis damage.
  • Therini Bio is valued at approximately $100.0M as of Oct 2026, set at its later-stage round, May 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $101.5M across 2 recorded rounds; the latest was Later Stage VC ($74.9M) in Mar 2023.
  • Notable investors include National Institutes of Health, University of California, Dolby Family Ventures, SV Health Investors, Angelini Ventures — 15 tracked in total.
  • Therini Bio has filed 3 Form Ds with the SEC since 2020, most recently Sep 2025 ($74.9M sold to 17 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$100.0M

Valued at $100.0M at its later-stage round, May 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Therini Bio with a free account
  • ·The complete investor list: 15 names
  • ·Watch Therini Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Therini Bio funding rounds

2 rounds
Mar 2023Later Stage VC$74.9MSEC filing▮
May 2019Early Stage VC$9.4MSEC filing▮
Full funding history →

Therini Bio valuation

Therini Bio was valued at $100 million at its later-stage round in May 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Therini Bio raised?

Therini Bio has raised $102 million across 2 recorded rounds since 2019. The largest was a $9.4 million early-stage round in May 2019; the most recent was a $74.9 million later-stage round in Mar 2023.

Therini Bio has filed 3 Form Ds with the SEC since 2020, most recently in Sep 2025 ($74.9 million sold to 17 investors).

Therini Bio investors

15 investors are on record for Therini Bio, including National Institutes of Health, University of California, Dolby Family Ventures and SV Health Investors. The later-stage round in Mar 2023 drew 17 investors.

About Therini Bio

Developer of biotechnology drugs designed to offer a potential treatment to protect the nervous system from multiple sclerosis damage. The company is engaged in the development of antibodies that are dedicated to the treatment of neuroinflammatory diseases due to vascular dysfunction, enabling healthcare providers to treat their patients and improve their lives.

Sector
Healthcare
HQ
Sacramento, CA, United States
Founded
2016
Employees
9
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.